The global prevalence of nonalcoholic fatty liver disease (NAFLD) has dramatically
increased in parallel with the epidemic of obesity. Controversy has emerged around dietary …

Background Nonalcoholic fatty liver disease (NAFLD) comprises hepatic alterations with
increased lipid accumulation (steatosis) without or with inflammation (nonalcoholic …

The lack of registered drugs for nonalcoholic fatty liver disease (NAFLD) is partly due to the
paucity of human-relevant models for target discovery and compound screening. Here we …

Patients with well-controlled LDL (low-density lipoprotein) levels still have residual
cardiovascular risk associated with elevated triglycerides. Epidemiological studies have …

Lifestyle intervention can be effective when treating non-alcoholic fatty liver diseases
(NAFLD) patients. Weight loss decreases cardiovascular and diabetes risk and can also …

This narrative review aims to discuss the more relevant evidence on the role of linoleic acid
(LA), a n-6 essential fatty acid that constitutes the predominant proportion of dietary …

Suboptimal nutrition is a leading cause of poor health. Nutrition and policy science have
advanced rapidly, creating confusion yet also providing powerful opportunities to reduce the …

Background & Aims The first-line treatment for non-alcoholic fatty liver disease (NAFLD) is
weight reduction. Several diets have been proposed, with various effects specifically on liver …

NAFLD is the world's most common chronic liver disease, and its increasing prevalence
parallels the global rise in diabetes and obesity. It is characterised by fat accumulation in the …

OBJECTIVE Nonalcoholic fatty liver disease (ie, increased intrahepatic triglyceride [IHTG]
content), predisposes to type 2 diabetes and cardiovascular disease. Adipose tissue …